CRISPR Therapeutics AG
GENE-EDITING COMPOSITIONS AND METHODS TO MODULATE FAAH FOR TREATMENT OF NEUROLOGICAL DISORDERS

Abstract:

The disclosure provides systems (e.g., CRISPR/Cas systems) for introducing an edit in a genomic DNA molecule comprising the fatty acid amide hydrolase gene (FAAH) and/or the FAAH pseudogene (FAAH-OUT). Also provided are methods for use of the systems, nucleic acids, delivery systems, and/or compositions described for genome editing to modulate the expression and/or activity of FAAH, for example, in a method of treating chronic pain.